8-K: Lifeward Ltd. Announces First Quarter 2025 Financial Results, Cites Progress in ReWalk Adoption and AlterG Growth

Lifeward Ltd. reports a slight revenue decrease year-over-year for Q1 2025, but highlights progress in ReWalk adoption, AlterG growth, and improved operating expense management.

Summary

• Lifeward Ltd. announced its Q1 2025 financial results, with revenue of $5.0 million compared to $5.3 million in Q1 2024.
• ReWalk, MyoCycle, and ReStore revenue was $1.7 million, down $0.8 million from the prior year, partly due to Medicare shipments recognized in Q1 2024.
• AlterG revenue increased by 17% to $3.3 million, driven by international demand.
• Gross margin improved to 42.2% from 26.4% in the prior year.
• Operating expenses decreased to $7.0 million from $7.9 million, due to cost savings from the closure of the Fremont location.
• Operating loss improved to $4.9 million from $6.5 million.
• Net loss was $4.8 million, or $0.46 per share, compared to $6.3 million, or $0.73 per share, in Q1 2024.
• As of March 31, 2025, Lifeward had $5.7 million in unrestricted cash and cash equivalents and no debt.
• The company raised $0.5 million through its ATM facility after the end of Q1.
• Lifeward continues to expect full-year revenue in the range of $28 million to $30 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While revenue is slightly down, there are significant improvements in gross margin and operating expenses, along with positive developments in product launches, partnerships, and market access. The company is also managing its cash effectively.

Positives

• The launch of ReWalk 7 in the U.S. market and the first commercial health insurance claim approval are significant milestones.
• Partnerships with CorLife and MYOLYN expand market reach and distribution channels.
• The agreement with BARMER in Germany provides access to a large covered population.
• AlterG revenue growth of 17% indicates strong demand.
• Gross margin improvement to 42.2% reflects a more favorable product mix and operating leverage.
• Operating expense reduction demonstrates effective cost management.
• The company expects quarterly cash burn to decline sequentially throughout the rest of the year.

Negatives

• Overall revenue decreased slightly from $5.3 million to $5.0 million year-over-year.
• Revenue from ReWalk, MyoCycle, and ReStore decreased by $0.8 million compared to the prior year.
• The company had a net loss of $4.8 million, although this is an improvement from the $6.3 million loss in the same quarter last year.

Risks

• Acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients is uncertain.
• The company's ability to achieve reimbursement from third-party payors, including CMS, for its products is a risk.
• The company's limited operating history and its ability to leverage its sales, marketing, and training infrastructure pose challenges.
• The company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers is a risk.
• The company's ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer is a risk.
• The company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others is a risk.

Future Outlook

Lifeward continues to expect full-year revenue in the range of $28 million to $30 million for 2025.

Management Comments

• During the first quarter of 2025, we experienced improvement in the throughput of Medicare claims submissions as a greater number of qualified leads moved towards the final stages of claims preparation, said Larry Jasinski, Chief Executive Officer.
• We also gained greater clarity on the documentation requirements for Medicare claims from the Medicare Administrative Contractors who process them, which we expect to result in shorter cycle time for approval and payment of future claims.

Industry Context

The announcement reflects Lifeward's efforts to expand its market presence in the rehabilitation and recovery sector, focusing on innovative medical technology solutions. The company is working to increase adoption of its ReWalk exoskeleton and grow its AlterG business, while also managing costs and improving operational efficiency.

Comparison to Industry Standards

• Comparing Lifeward to companies like Ekso Bionics and Myomo, which also develop and market exoskeletons, Lifeward's focus on both personal and rehabilitation exoskeletons provides a diversified approach.
• The 17% growth in AlterG revenue is a positive sign, as other companies in the rehabilitation equipment market, such as Hocoma, are also experiencing growth due to increased demand for advanced rehabilitation technologies.
• The improvement in gross margin to 42.2% is a positive trend, bringing it closer to industry benchmarks for medical device companies.

Stakeholder Impact

• Shareholders: The improved financial performance and positive developments in product launches and partnerships are likely to be viewed favorably by shareholders.
• Employees: The cost savings from the closure of the Fremont location may have impacted employees, but the company's continued growth and innovation efforts could create new opportunities.
• Customers: The launch of ReWalk 7 and the expansion of the MyoCycle FES Cycling Therapy System provide customers with access to innovative medical technology solutions.
• Suppliers: The company's ability to obtain certain components of its products from third-party suppliers is crucial for its continued operations.
• Creditors: The company's strong cash position and lack of debt are positive indicators for creditors.

Next Steps

• Continue to drive adoption of ReWalk 7 in the U.S. market.
• Expand coverage beyond Medicare to the commercial health insurance segment.
• Leverage partnerships with CorLife and MYOLYN to increase sales and market penetration.
• Streamline access to ReWalk Personal Exoskeletons for eligible beneficiaries in Germany through the agreement with BARMER.
• Focus on improving the throughput of Medicare claims submissions and reducing cycle time for approval and payment of future claims.

Key Dates

Keywords

Lifeward, ReWalk, AlterG, Exoskeleton, Financial Results, Q1 2025, Revenue, Medicare, Healthcare, Medical Technology